May 10th 2024
Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according to a recent study.
Imetelstat Offers Benefits for Patients With MDS Who Are Red Blood Cell–Transfusion Dependent
December 5th 2023The past year has offered new hope for patients with lower-risk myelodysplastic syndromes. Besides imetelstat, which has an FDA deadline for action of June 2024, the agency approved luspatercept, which has a different mechanism of action.
Read More
Minimizing Terms for Toxicity Often Used in Multiple Myeloma Trials, Study Says
November 22nd 2023A cohort study of 65 clinical trials in multiple myeloma found that toxic effects are often described with subjective terminology that may not reflect adverse event rates reported in the studies.
Read More
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More
ASN Kidney Week Returns to Philadelphia to Highlight Latest Innovations, Issues in Renal Care
October 30th 2023The American Society of Nephrology (ASN) Kidney Week 2023 will take place in Philadelphia, Pennsylvania, from November 2-5, as experts from across the globe gather to discuss the latest innovations in renal care and current issues facing the field.
Read More
Overcoming the Efficacy-Effectiveness Gap in Cancer Therapy Research
October 21st 2023With stringent criteria, randomized controlled trials are the cornerstone of cancer intervention research, but the result is they do not represent the majority of patients, which leads to a gap between the efficacy seen in trials and the effectiveness in the real-world setting.
Read More
Novel Approaches to Head and Neck Cancer at Vanderbilt Ingram Cancer Center
October 12th 2023Speakers at an Institute for Value-Based Medicine event with Vanderbilt University Medical Center highlighted the novel therapies and techniques being used to improve outcomes for patients with head and neck cancer.
Read More
Updates Are Driving the Field of MDS Forward, but Changes Still Needed
September 25th 2023In just the last 2 years there have been updates in classification, risk assessment, and response criteria in myelodysplastic syndromes (MDS), but additional efforts are needed to improve these, and there remains a need for better therapies.
Read More
Novel PET-Based Radiomics Signature Predicts CAR T Efficacy in DLBCL
September 15th 2023A PET-based radiomics signature was able to predict the efficacy of chimeric antigen receptor (CAR) T-cell therapy and performed better than conventional PET biomarkers in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Read More
Ponatinib Plus Chemotherapy Elicits MRD-Negative Remissions in Certain Patients With ALL
September 9th 2023Ponatinib also produces an improvement in progression-free survival compared with imatinib among those with Philadelphia chromosome-positive acute lymphoblastic leukemia in the phase 3 PhALLCON trial.
Read More
Review Highlights Knowledge Gaps in Lymphoma Treatment Outcomes in AYAs
September 7th 2023The review summarized existing evidence around short- and long-term treatment-related toxicities among adolescents and young adults (AYAs), as well as gaps in care guidelines for AYA survivors of lymphoma.
Read More
Standard Uptake Value Index May Aid in Diagnosis of Polymyalgia Rheumatica
August 8th 2023Polymyalgia rheumatica (PMR) is an inflammatory disease often misdiagnosed as certain cancers, among other diseases. Researchers have recently made progress to better diagnose PMR using a standard uptake value index based on fluorodeoxyglucose with positron-emission tomography/computed tomography.
Read More
ASCO 2023: Leukemia and Lymphoma
July 31st 2023Results include a landmark study that involved seamless collaboration across adult and pediatric patient groups, leading to a highly diverse study population. Other coverage addresses access to novel therapies and what's coming in the pipeline, including CAR T-cell therapy with tyrosine kinase inhibitors.
Read More
Cell Protein GRP78 Affects Cancer Cell Spread, USC Study Reveals
July 25th 2023New research suggests that when cancer cells are under stress, cellular chaperone protein GRP78 alters its behavior and migrates to the cell's nucleus, where it modifies gene activities and allows cancer cells to become more mobile and invasive.
Read More
The successful collaboration between a primary care–based network of practices and academic researchers demonstrates feasibility and the need for more funding for primary care research.
Read More
Characteristics of Relapse Affect Treatment Choices in Multiple Myeloma
April 3rd 2023Natalie S. Callander, MD, director of the University of Wisconsin Carbone Cancer Center Myeloma Clinical Program, reviewed the treatment landscape at the National Comprehensive Cancer Network (NCCN) 2023 Annual Conference.
Read More
Study of South African Males With Prostate Cancer Reveals Limits of Current Germline Testing
March 10th 2023The findings, published in the Journal of the National Comprehensive Cancer Network, add to the evidence that the shift to precision medicine is built on data that have not included sufficient numbers of patients of color.
Read More
42 Health Systems Picked for PCORI Plan to Move Clinical Research to Practice
March 3rd 2023Seeking to speed up the execution of evidence-based care practices, the Patient-Centered Outcomes Research Institute (PCORI) announced the 42 health systems across the country who will join a 5-year program to build capacity and implementation to improve health care outcomes.
Read More
BRVO, CRVO Need More Effective Long-term Therapies
February 12th 2023While the current therapies are effective for treating branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO), they are inadequate for long-term treatment in clinical practice, according to an analysis of real-world data.
Read More